The Impact of Sarcopenia on Clinical Outcomes in Pediatric Crohn’s Disease
1. In children with Crohn’s disease (CD), sarcopenia at diagnosis was associated with a greater chance of relapse in the ...
Tag: Crohn’s Disease
Long-term Outcomes of Patients with Crohn’s Disease Treated with Risankizumab
1. In adult patients with Crohn’s disease (CD) treated with risankizumab, only 13% of patients experienced treatment failure while 23% ...
2 Minute Medicine Rewind September 1, 2025
β-Blocker Use and Health Status Among Patients With Heart Failure With Preserved Ejection Fraction 1. In patients with heart failure ...
Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with ...
Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease
1. In patients with Crohn’s disease (CD), fecal calprotectin (FC) was a useful biomarker for monitoring small bowel lesions and ...
Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis
1. Rectoscopy alone for evaluation of endoscopic and histologic remission of ulcerative colitis (UC) had good accuracy and is sufficient ...
Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease
1. Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) were effective imaging modalities for the assessment of the radiologic response ...
Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia
1. In postmenopausal patients with ulcerative colitis (UC) or Crohn’s disease (CD), approximately one-third had osteoporosis while approximately 40% had ...
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
Fecal Microbiota, live-jslm may be an effective means of preventing Clostridiodes difficile infections in patients with inflammatory bowel disease
1. The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection (rCDI) in patients ...
